StockMacro
Company, fund or insider

Help

Menu

Rapport Therapeutics

$23.16 -42% in 6 monthsMarket cap $1.4B

RAPP on XNAS, Health Care, Rapport Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Insiders bought $22M in 90 days but short interest jumped 30% on the latest report.

  • BadNet loss of $150.5M over twelve months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Industry
Pharmaceutical preparations (Health Care)
Employees
84
Website
rapportrx.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 9 Mar 2027 (an estimate: a year ago it reported on 10 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $40.2M.
Quarter to 31 Mar 2023: revenue –, net income -$6.1MQuarter to 30 Jun 2023: revenue –, net income -$6.4MQuarter to 30 Sep 2023: revenue –, net income -$8.7MQuarter to 31 Dec 2023: revenue –, net income -$13.5MQuarter to 31 Mar 2024: revenue –, net income -$22.7MQuarter to 30 Jun 2024: revenue –, net income -$18.1MQuarter to 30 Sep 2024: revenue –, net income -$17.5MQuarter to 31 Dec 2024: revenue –, net income -$20.0MQuarter to 31 Mar 2025: revenue $0, net income -$24.1MQuarter to 31 Mar 2025: revenue $0, net income -$24.1MQuarter to 30 Jun 2025: revenue $0, net income -$26.7MQuarter to 30 Jun 2025: revenue $0, net income -$26.7MQuarter to 30 Sep 2025: revenue $0, net income -$26.9MQuarter to 30 Sep 2025: revenue $0, net income -$26.9MQuarter to 31 Dec 2025: revenue –, net income -$33.8MQuarter to 31 Mar 2026: revenue $20.0M, net income -$19.9MQuarter to 31 Mar 2026: revenue $20.0M, net income -$19.9MQuarter to 30 Jun 2026: revenue $0, net income -$56.6MQuarter to 30 Jun 2026: revenue $0, net income -$56.6MQuarter to 30 Sep 2026: revenue $0, net income -$40.2MQuarter to 30 Sep 2026: revenue $0, net income -$40.2M
31 Mar 2023RevenueNet incomeNet losstallest bar $56.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$40.2M
30 Jun 2026$0-$56.6M
31 Mar 2026$20.0M-$19.9M
31 Dec 2025–-$33.8M
30 Sep 2025$0-$26.9M
30 Jun 2025$0-$26.7M
31 Mar 2025$0-$24.1M
31 Dec 2024–-$20.0M
30 Sep 2024–-$17.5M
30 Jun 2024–-$18.1M
31 Mar 2024–-$22.7M
31 Dec 2023–-$13.5M
30 Sep 2023–-$8.7M
30 Jun 2023–-$6.4M
31 Mar 2023–-$6.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$150.5M -$97.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.16 -$2.26
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -33.3% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$77.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $395.0M $513.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$395.0M (net cash) -$513.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.60
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.5 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Rapport TherapeuticsRAPP (this company) $1.4Bloss–––
AnaptysBioANAB $1.4B7.57.2+13%96.3%
uniQureQURE $1.4Bloss67.3+28%–
UroGen PharmaURGN $1.4Bloss5.4+159%-26.3%
Tyra BiosciencesTYRA $1.4Bloss–––
Phibro Animal HealthPAHC $1.4B13.20.88+10%6.7%

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$17.6M

bought $22.0M, sold $4.5M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.0%

168 13F filers vs 160

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

85%

50.1M shares held by 13F filers (30 Sep 2026) of 59.3M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.7%

4.0M shares sold short (30 Oct 2026) of 59.3M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.8

4.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+30%

3.1M shares sold short in the report before, 4.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

56%

56% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 64%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

14

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

8 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Insider buying $1.4M, 3 insiders

Price $23.16 on 20 Nov 2026, -14% over 12 months (12-month range $22.50 to $52.50)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $24.7M in the last 12 months (the 12 months before: -$2.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $78K in the latest quarter, +255% on a year earlier.
Institutional holders (13F filers). 168 13F filers reported holding it in the latest 13F quarter, +40% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
22 Oct 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 1.4M)
16 Sep 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 1.6M)
3 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
17 May 20248-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Jun 2024: $9.5M published
Month from 1 Jul 2024: $1.1M published
Month from 1 Mar 2025: $70K published
Month from 1 Apr 2025: -$81K published
Month from 1 May 2025: -$81K published
Month from 1 Jun 2025: -$94K published
Month from 1 Jul 2025: -$119K published
Month from 1 Aug 2025: -$127K published
Month from 1 Sep 2025: -$803K published
Month from 1 Oct 2025: -$501K published
Month from 1 Nov 2025: -$489K published
Month from 1 Dec 2025: -$729K published
Month from 1 Jan 2026: -$796K published
Month from 1 Feb 2026: -$567K published
Month from 1 Mar 2026: -$362K published
Month from 1 Apr 2026: -$19.0M published
Month from 1 May 2026: -$17.2M published
Month from 1 Jul 2026: -$1.2M published
Month from 1 Aug 2026: -$5.9M published
Month from 1 Sep 2026: -$461K published
Month from 1 Oct 2026: $21.5M published
H-1B/E-3 applications certified
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 31 Mar 2025: $0; public on 8 May 2026
Quarter ended 30 Jun 2025: $0; public on 6 Aug 2026
Quarter ended 30 Sep 2025: $0; public on 5 Nov 2026
Quarter ended 31 Mar 2026: $20.0M; public on 8 May 2026
Quarter ended 30 Jun 2026: $0; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2023: $52K; public on 8 Nov 2024
Quarter ended 31 Dec 2023: $1.4M; public on 12 Mar 2025
Quarter ended 31 Mar 2024: $1.1M; public on 9 May 2025
Quarter ended 30 Jun 2024: $967K; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $140K, +169% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $226K, -84% on a year earlier; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $291K, -73% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $22K, -98% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $134K, -4.3% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $169K, -25% on a year earlier; public on 11 Mar 2026
Quarter ended 31 Mar 2026: $86K, -70% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $78K, +255% on a year earlier; public on 6 Aug 2026
Institutional holders (13F filers)
30 Jun 2024 report: 34; public on 14 Aug 2024
30 Sep 2024 report: 53; public on 14 Nov 2024
31 Dec 2024 report: 68; public on 14 Feb 2025
31 Mar 2025 report: 75; public on 15 May 2025
30 Jun 2025 report: 78; public on 14 Aug 2025
30 Sep 2025 report: 120; public on 14 Nov 2025
31 Dec 2025 report: 140; public on 17 Feb 2026
31 Mar 2026 report: 143; public on 15 May 2026
30 Jun 2026 report: 160; public on 14 Aug 2026
30 Sep 2026 report: 168; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 3 insiders buy $1.4M of its shares on the open market within 30 days (3 filings).
  • Clustered insider buying: had 3 insiders buy $1.4M of its shares on the open market within 30 days (3 filings) Public on 22 Oct 2026.
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 59 insider trades

Last 90 days: 7 sales, $4.5M; 7 purchases, $22.0M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
30 Oct 2026James HealyDirectorBuy969,480$21.00$20.4MForm 4
23 Oct 2026Abraham CeesayChief Executive OfficerSellplanned in advance (10b5-1)2,210$29.16$64KForm 4
23 Oct 2026Ramiro SanchezDirectorBuy3,600$27.35$98KForm 4
22 Oct 2026Paul M SilvaDirectorBuy3,680$27.07$100KForm 4
22 Oct 2026Wendy B. YoungDirectorBuy3,789$26.39$100KForm 4
22 Oct 2026Steven M PaulDirectorBuy35,714$27.28$974KForm 4
22 Oct 2026John MaraganoreDirectorBuy9,411$26.45$249KForm 4
21 Oct 2026Troy A. IgnelziChief Financial OfficerBuy5,500$26.10$144KForm 4

168 institutions reported shares at the end of Q3 2026, 85% of the shares outstanding; 29 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)7.2M12.1%$241.8M+24K+0.3%
TRV GP V, LLC6.3M10.6%$211.0MNo change
ARCH Venture Management, LLC3.7M6.29%$125.3MNo change
Goldman Sachs Group Inc3.0M5.02%$99.9M+63K+2.2%
BlackRock, Inc.2.9M4.86%$96.8M+181K+6.7%
Capital International Investors2.7M4.48%$89.2M-268K-9.2%
Cormorant Asset Management, LP2.5M4.15%$82.6M-200K-7.5%
Sofinnova Investments, Inc.1.9M3.21%$64.0MNo change
Johnson & Johnson1.8M3.01%$60.0MNo change
Polar Capital Holdings Plc1.6M2.71%$53.9M-4,932-0.3%

Company events

All 5 company events

In 12 months: 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Oct 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
10 Sep 2025Signed a major agreement8-K
10 Jun 2024Signed a major agreementSame filing: sold shares privately, changed its bylaws or fiscal year8-K
3 Jun 2024Registered new securities for sale (S-1)S-1/A
17 May 2024Registered new securities for sale (S-1)S-1

14 open postings; careers site tracked since 20 Nov 2026. Most in Legal, policy & compliance 29%, Operations & administration 29%, Program & project management 21%, People & recruiting 7%.

PostedJobLocation
5 Nov 2026Senior Director, Regulatory Strategy Program LeadProgram & project management99 High Street, Suite 2100 , Boston, MA 02110
27 Oct 2026Clinical Study Start-Up AssociateOperations & administration99 High Street, Suite 2100 , Boston, MA 02110
27 Oct 2026Clinical Systems Manager, Clinical Data ManagementProgram & project management99 High Street, Suite 2100 , Boston, MA 02110
27 Oct 2026Manager, Clinical Supply ChainSupply chain & procurement99 High Street, Suite 2100 , Boston, MA 02110
13 Oct 2026Sr. Clinical Trial AssociateOperations & administration99 High Street, Suite 2100 , Boston, MA 02110
5 Oct 2026Senior Manager, Trial Awareness & RecruitmentPeople & recruiting99 High Street, Suite 2100 , Boston, MA 02110
22 Sep 2026Director, Clinical ContractsLegal, policy & compliance99 High Street, Suite 2100 , Boston, MA 02110
12 Aug 2026Sr. Clinical Trial AssociateOperations & administration99 High Street, Suite 2100 , Boston, MA 02110

The 5 newest of 116 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 30 Oct 2026Insiders record

    HEALY JAMES (director) bought 969,480 shares of RAPP ($20.4M)

  2. 23 Oct 2026Insiders record

    Sanchez Ramiro (director) bought 3,600 shares of RAPP ($98,478)

  3. 22 Oct 2026Insiders change

    had 3 insiders buy $1.4M of its shares on the open market within 30 days (3 filings).

    Who bought: Ignelzi Troy A., Maraganore John, Paul Steven M.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $1.4M
    Window
    22 Sep 2026 to 22 Oct 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  4. 22 Oct 2026Insiders record

    Silva Paul M (director) bought 3,680 shares of RAPP ($99,636)

  5. 22 Oct 2026Insiders record

    Young Wendy B. (director) bought 3,789 shares of RAPP ($99,992)

  6. 22 Oct 2026Insiders record

    PAUL STEVEN M (director) bought 35,714 shares of RAPP ($974,278)

  7. 22 Oct 2026Insiders record

    MARAGANORE JOHN (director) bought 9,411 shares of RAPP ($248,891)

  8. 21 Oct 2026Insiders record

    Ignelzi Troy A. (Chief Financial Officer) bought 5,500 shares of RAPP ($143,550)

  9. 16 Sep 2025Insiders change

    had 3 insiders buy $1.6M of its shares on the open market within 30 days (3 filings).

    Who bought: Young Wendy B., Paul Steven M, Huber Reid M.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $1.6M
    Window
    17 Aug 2025 to 16 Sep 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  10. 16 Sep 2025Insiders record

    Huber Reid M (director) bought 20,400 shares of RAPP ($499,392) (dated 15 Sep 2025)

  11. 16 Sep 2025Insiders record

    PAUL STEVEN M (director) bought 41,666 shares of RAPP ($1.0M) (dated 15 Sep 2025)

  12. 12 Sep 2025Insiders record

    Young Wendy B. (director) bought 3,500 shares of RAPP ($79,100) (dated 11 Sep 2025)

  13. 14 Mar 2025Insiders record

    Young Wendy B. (director) bought 6,000 shares of RAPP ($61,260) (dated 13 Mar 2025)

  14. 14 Mar 2025Insiders record

    Ignelzi Troy A. (Chief Financial Officer) bought 10,000 shares of RAPP ($100,988) (dated 13 Mar 2025)

  15. 4 Jul 2024Insiders record

    HEALY JAMES (director) bought 44,032 shares of RAPP ($1.1M) (dated 3 Jul 2024)

  16. 11 Jun 2024Insiders record

    HEALY JAMES (director) bought 558,824 shares of RAPP ($9.5M) (dated 10 Jun 2024)

  17. 3 Jun 2024Filings record

    Registered new securities for sale (S-1)

  18. 17 May 2024Filings record

    Registered new securities for sale (S-1)

Not listed: 78 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002012593
Ticker
RAPP
Domain
rapportrx.com
Employer name
Rapport Therapeutics, Inc. (1 unverified)
Fein
88-0724208 (1 unverified)
Hq location
MA|BOSTON|02110 (1 unverified)
Name
Rapport Therapeutics, Inc.
  • DOL H-1B labor condition applications and PERM certifications5 data points23 Mar 2026 to 23 Mar 2026
  • SEC Form 13F institutional holdings90 data points30 Jun 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)35 records17 May 2024 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)199 data points31 Dec 2022 to 2 Nov 2026
  • SEC Form 4 insider transactions59 records, 184 data points10 Jun 2024 to 30 Oct 2026
  • FINRA short interest (twice monthly)173 data points14 Jun 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1234 data points7 Jun 2024 to 20 Nov 2026